CPRX
$23.33
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
Intraday
Recent News
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU
AZN wins the EU nod for Imfinzi in early gastric and GEJ cancers, backed by strong survival data and expanding its blockbuster oncology footprint.
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as mid-to-late-stage studies advance.
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Softness
What Catalyst Pharmaceuticals Stock’s Recent Returns Tell You Catalyst Pharmaceuticals (CPRX) has been relatively steady over the past year, with a 7% total return, even as the stock has seen a 6% decline over the past month and 4% over the past 3 months. See our latest analysis for Catalyst Pharmaceuticals. At a share price of $23.23, recent momentum has softened, with a 7 day share price return showing a decline of 6.29% and a 30 day share price return showing a decline of 4.52%, even as...
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Long Term Value After Rare Disease Interest?
If you are looking at Catalyst Pharmaceuticals and wondering whether the recent price level offers good value, this article will walk through what the current market price might be implying. The stock last closed at US$23.23, with returns of 0.3% year to date, 10.5% over 1 year, 45.9% over 3 years, and a very large gain over 5 years. This comes alongside recent 7 day and 30 day declines of 4.2% and 4.5%. Recent news around Catalyst Pharmaceuticals has focused on its role in the...